4516:TSENippon Shinyaku Co., Ltd. Analysis

Nippon Shinyaku is trading well below its 20‑day, 50‑day and 200‑day moving averages, signaling a short‑term downtrend, yet the RSI sits in the oversold region and the MACD has turned bullish, hinting at a potential rebound. The stock’s price‑to‑earnings ratio of under 9 is dramatically lower than the industry average of roughly 25, and the price‑to‑book is under 1, suggesting a clear value gap. A dividend yield above 3% with a modest payout ratio reinforces cash‑flow stability, while the DCF‑derived fair value is more than double the current price, implying ~40% upside.
Fundamentally, revenue is growing double‑digits year‑over‑year, margins remain healthy, and the balance sheet is strong with cash far exceeding debt. The pipeline of specialty drugs in early clinical phases adds a growth catalyst, but regulatory approvals present a medium‑level risk. Volatility is high, yet beta is low, and trading volume has been tapering, which tempers liquidity considerations.